CN113846099B - siRNA for knocking down pig SAMHD1 gene expression, kit and application thereof - Google Patents
siRNA for knocking down pig SAMHD1 gene expression, kit and application thereof Download PDFInfo
- Publication number
- CN113846099B CN113846099B CN202111117202.0A CN202111117202A CN113846099B CN 113846099 B CN113846099 B CN 113846099B CN 202111117202 A CN202111117202 A CN 202111117202A CN 113846099 B CN113846099 B CN 113846099B
- Authority
- CN
- China
- Prior art keywords
- sirna
- pig
- lentivirus
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 44
- 101150114242 SAMHD1 gene Proteins 0.000 title claims abstract description 20
- 230000014509 gene expression Effects 0.000 title claims abstract description 13
- 241000713666 Lentivirus Species 0.000 claims abstract description 19
- 208000015181 infectious disease Diseases 0.000 claims abstract description 12
- 108091081021 Sense strand Proteins 0.000 claims abstract description 5
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 5
- 239000013612 plasmid Substances 0.000 claims description 19
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 238000012761 co-transfection Methods 0.000 claims description 3
- 208000021601 lentivirus infection Diseases 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 60
- 238000001890 transfection Methods 0.000 description 26
- 238000003197 gene knockdown Methods 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 238000003384 imaging method Methods 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 4
- 102000047164 SAM Domain and HD Domain-Containing Protein 1 Human genes 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- BKCJZNIZRWYHBN-UHFFFAOYSA-N Isophosphamide mustard Chemical compound ClCCNP(=O)(O)NCCCl BKCJZNIZRWYHBN-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of molecular biology and cell biology preparation, and discloses siRNA for knocking down pig SAMHD1 gene expression, a kit and application thereof, wherein a sense strand of the siRNA is a base sequence shown in SEQ ID NO.1, and an antisense strand of the siRNA is a base sequence shown in SEQ ID NO. 2. The siRNA for knocking down the pig SAMHD1 gene expression has high knocking efficiency, is suitable for pig-derived cell infection experiment operation taking lentivirus as a tool, can obviously improve the lentivirus infection efficiency of the pig-derived cell, and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of molecular biology and cell biology preparation, and relates to siRNA for knocking down pig SAMHD1 gene expression, a kit and application thereof.
Background
Lentiviruses belong to the family retroviridae, and are characterized by a long latency period which causes the individual to exhibit significant clinical symptoms more than the primary infection in macrophages and lymphocytes. The commonly used lentivirus vector is human immunodeficiency I type virus (HIV-1), and has the advantages of wide infection, effective infection of cells in a division stage and a stationary stage, insertion of large genetic fragments into host chromatin, long-term maintenance of stable transgene expression and the like, thereby being a favorable tool for introducing exogenous genes. The use of lentiviral vectors is limited by the infection efficiency of the lentivirus. In addition, no knockdown gene has been found that can increase the infection efficiency of different cells.
Disclosure of Invention
The invention aims to provide siRNA and a kit for knocking down pig SAMHD1 gene expression and application thereof, the gene knocking efficiency is high, and the lentivirus infection efficiency of different pig source cells can be obviously improved.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides siRNA for knocking down pig SAMHD1 gene expression, wherein a sense strand of the siRNA is a base sequence shown in SEQ ID NO.1, and an antisense strand of the siRNA is a base sequence shown in SEQ ID NO. 2.
The invention also provides a kit containing the siRNA.
Preferably, the kit further comprises a lentiviral packaging plasmid; the lentivirus packaging plasmid comprises three circular plasmids of pLenti-gfp, pMD2G and pSPAX 2.
Preferably, the lentiviruses are packaged using co-transfection with three circular plasmids in a molar ratio of 1:1:1, pLenti-gfp, pMD2G and pSPAX 2.
Preferably, the siRNA is transfected into cells requiring a final concentration of 150nM/μ L.
Preferably, the siRNA is transfected into the cell at the time of transfection within 12h before the cell is infected by the lentivirus.
The invention also provides application of the kit in improving the efficiency of infecting the porcine cells with the lentiviruses.
Compared with the prior art, the invention has the beneficial effects that:
the siRNA for knocking down the pig SAMHD1 gene expression has high knocking efficiency, is suitable for pig source cell infection experiment operation taking lentivirus as a tool, can obviously improve the lentivirus infection efficiency of different pig source cells (such as IPAM and BMDM), and has wide application prospect.
Drawings
FIG. 1 shows the efficiency of knocking down SAMHD1 gene expression in pigs transfected by different siRNAs.
FIG. 2 shows knockdown efficiency of siRNA-5 at different final concentrations of transfection.
FIG. 3 shows the knockdown efficiency of siRNA-5 after different times of transfection.
FIG. 4 shows the results observed by fluorescence inverted microscope 24h after cotransfection of plasmids.
FIG. 5 shows the fluorescent quantitative PCR amplification curve of siRNA-5.
FIG. 6 shows a melting curve of fluorescent quantitative PCR.
FIG. 7 shows the siRNA-5 knockdown efficiency assay results.
FIG. 8 shows the results of microscopic imaging of IPAM cells at the 36hpi time point.
FIG. 9 shows the results of microscopic imaging of IPAM cells at 48hpi time point.
FIG. 10 shows the results of microscopic imaging of IPAM cells at the 60hpi time point.
FIG. 11 shows the results of microscopic imaging of IPAM cells at the 72hpi time point.
FIG. 12 shows the results of microscopic imaging of IPAM cells at the 84hpi time point.
FIG. 13 shows the results of microscopic imaging of IPAM cells at the 96hpi time point.
FIG. 14 shows the results of microscopic imaging of IPAM cells at 108hpi time point.
Fig. 15 shows the results of flow cytometry cell clustering of IPAM cells in each well that were detoxified at MOI ═ 100.
Fig. 16 shows the results of flow cytometry cell clustering of BMDM cells in each well that were inoculated at MOI ═ 100.
Detailed Description
The following examples are intended to illustrate the invention, but are not intended to limit the scope of the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art. The test methods in the following examples are conventional methods unless otherwise specified. The reagents used in the following examples are all analytical grade reagents and are commercially available.
Example one pig SAMHD1 Gene knockdown efficiency assay
1.1 siRNA design
5 pairs of siRNA combinations, designated as siRNA-1, siRNA-2, siRNA-3, siRNA-4, and siRNA-5, were designed based on the published pig SAMHD1 gene sequence (NM-001292105.1) from the NCBI database and were synthesized by Shanghai Jima pharmaceutical technology, Inc., and the sequences are shown in Table 1.
TABLE 1siRNA designed according to pig SAMHD1 Gene
1.2 transfection with siRNA
When the IPAM cell density was 80%, siRNA was transfected into IPAM cells using the jetPRIME Polyplus Transfection kit (Ref #114-15/1.5mL), and the final concentrations of Transfection were selected as blank (NC), 50 nM/. mu.L, 100 nM/. mu.L, 150 nM/. mu.L and 200 nM/. mu.L, respectively. The medium was changed to an equal volume of serum-free RPMI 1640 medium 4-6h after siRNA transfection.
1.3 Lentiviral packaging
1.3.1 calculation of transfection volume of each plasmid
Three circular plasmid concentrations, pLenti-gfp, pMD2G and pSPAX2, were determined using a NanoDrop one ultramicro spectrophotometer. The mass of each plasmid to be transfected was calculated at a total mass of 10. mu.g transfected based on the nucleic acid chain length of each plasmid at a molar ratio of 1:1:1, and the results are shown in Table 2. A jetPRIME Polyplus Transfection kit containing siRNA and three circular plasmids was prepared.
TABLE 2 plasmid masses at transfection
1.3.2 Co-transfection of plasmids
A10 mL volume of 293T cell suspension at 2X 105Placing the cells in a 10cm cell culture dish at a density of/mL until the cell number grows to 6X 106Then, the jetPRIME Polyplus Transfection kit (Ref #114-15/1.5mL) was used to supply the kitThe plasmids were co-transfected into 293T cells according to the calculated volume, and the cell culture supernatant was replaced with 10mL serum-free DMEM medium 4h after transfection.
1.3.3 Lentiviral Collection and storage
And (3) after the plasmid is cotransfected for 48h, packaging the lentivirus, placing the packaged lentivirus in a refrigerator at the temperature of-80 ℃ by using a 10cm cell culture dish, repeatedly freezing and thawing, collecting a culture dish liquid phase in a sterile 15mL centrifuge tube, centrifuging at 2000rpm for 5min, and collecting a supernatant. Filtering the supernatant with 0.45 μm filter membrane, and packaging in sterile 1.5ml microfuge tube, or storing in-80 deg.C refrigerator.
1.4 lentivirus infection of IPAM cells
The porcine source cells to be treated in the experiment are respectively infected by the lentivirus 12h, 24h and 36h after siRNA transfection. Lentivirus-gfp was used as the positive control for the target experiment.
1.4.1siRNA transfection IPAM cell suspension was transfected at 2X 10 volumes of 2mL per well5The density of each/mL is respectively placed in a 6-well cell culture plate, 12mL is used in 6 wells, and when the cell density grows to about 80%, siRNA provided by a jet PRIME Polyplus Transfection kit (Ref #114-15/1.5mL) is used for transfecting siRNA provided by the kit into 3-well cells at a final concentration of 150 nM/. mu.L to serve as an experimental group; the cells in the other 3 wells were transfected with NC-siRNA at the same concentration as a control group.
The nucleic acid sequence of NC-siRNA is as follows: sense strand: 5'-UUCUCCGAACGUGUCACGUTT-3', respectively; antisense strand: 5'-ACGUGACACGUUCGGAGAATT-3' are provided.
4h after siRNA transfection, the culture medium of each group of cells was replaced by an equal volume of serum-free RPMI 1640 medium.
1.5.2RNA extraction and reverse transcription
After 12h of transfection, cell pellets from each well were collected, and RNA from the cell pellets was extracted by TRIZOL lysis method and dissolved in 30. mu.L of RNase-free water.
Using reverse transcription kit (TAKARA PrimeScript)TMRT Master Mix, RR036A) reverse transcribe the extracted RNA into cDNA, either for immediate use or for storage at-20 ℃.
1.5.3 fluorescent quantitation PCR detection of siRNA knockdown efficiency
TABLE 3 fluorescent quantitative PCR reaction System
And the detection primers comprise a SAMHD1 detection primer and a beta-actin detection primer.
The nucleic acid sequences of the SAMHD1 detection primer pair are as follows:
an upstream primer: 5'-TGGCAAATAAAAGAAATGGC-3'
An upstream primer: 5'-CTCACAGACACGGGCGAAT-3' are provided.
The beta-actin detection primer nucleic acid has the following sequence:
an upstream primer: 5'-CCGCACCACTGGCATTGTC-3'
A downstream primer: 5'-CTCCTTGATGTCCCGCACG-3' are provided.
1.5.4siRNA knockdown efficiency calculation
And (3) measuring the ct value of each sample according to the fluorescent quantitative PCR, calculating the siRNA knocking efficiency, and calculating the siRNA knocking efficiency by using GraphPad Prism 6 statistical analysis software.
1.5.5 results and analysis
The efficiency of knocking down the gene expression of the pig SAMHD1 by different siRNA transfections is shown in FIG. 1. As can be seen from FIG. 1, the knockdown efficiency of siRNA-5 was the best, and siRNA-5 was finally identified.
Knockdown efficiency of siRNA-5 at different final transfection concentrations is shown in FIG. 2. As can be seen from FIG. 2, siRNA transfection requires a final concentration of 150nM/μ L for knockdown efficiency and economy.
The knockdown efficiency of siRNA-5 after different times of transfection is shown in FIG. 3. As can be seen in FIG. 3, the percentage increase in GFP fluorescence was most efficient when the lentivirus was reinfected 12h after transfection, so the siRNA transfection was selected 12h before lentivirus infection.
The results of 24h after cotransfection of the plasmids observed by a fluorescence inverted microscope are shown in FIG. 4, wherein 1 is a control group and 2 is an experimental group, and cells are observed to emit green fluorescence under the fluorescence inverted microscope.
The fluorescent quantitative PCR amplification curve of siRNA-5 is shown in FIG. 5, wherein the red curve (upper part) in the figure represents that the detection primer targets beta-actin gene; the blue curve (below) represents its detection primer targeting SAMHD1 gene. As can be seen from FIG. 5, each sample to be tested exhibits an S-shaped amplification curve; negative samples had no amplification curve or ct values greater than 37.
The fluorescence quantitative PCR melting curve is shown in figure 6, wherein the red curve represents the detection primer targeting beta-actin gene; the blue curve represents its detection primer targeting SAMHD1 gene. As can be seen from FIG. 6, the two pairs of detection primers SAMHD1 and beta-actin each show independent peaks, and the peaks correspond to constant temperature.
The results of siRNA-5 knockdown efficiency assays are shown in FIG. 7. As can be seen from fig. 7, the knockdown efficiency of siRNA-5 reached 91.9%, the gene knockdown efficiency was high, and the difference was very significant compared to the control.
EXAMPLE two determination of lentivirus infection efficiency
2.1 Lentiviral packaging
See example 1.3.
2.2 transfection and grouping of siRNA IPAM cell suspension at 2X 10 at a volume of 1mL per well5The density of the/mL is set in 12-well cell culture plates, and 12mL is used in total for 1 plate. When the cell density is about 80%, transfecting siRNA provided by a jetPRIME Polyplus Transfection kit (Ref #114-15/1.5mL) into 6-well cells at a final concentration of 150 nM/. mu.L to serve as an experimental group; the cells in the other 6 wells were transfected with NC-siRNA at the same concentration as a control group. 4h after siRNA transfection, the culture medium was changed to serum-free RPMI 1640 medium for each group of cells.
2.3 lentivirus inoculation and grouping
To 3 of 6-well cells transfected with siRNA provided in the kit, Lenti-gfp was added at final MOI of 100, and this subset was designated as S1; in addition, the cells in the 3 holes are not subjected to virus inoculation treatment, and only DMEM serum-free culture medium with the same volume is added, wherein the grouping is marked as S0;
6-well cells transfected with NC-siRNA provided in the kit, to 3 of which was added Lenti-gfp at final MOI of 100, this grouping being designated NC 1; in addition, the 3-hole cells are not subjected to virus inoculation treatment, and only DMEM serum-free culture medium with the same volume is added, and the group is marked as NC 0;
after the lentivirus is inoculated for 2 hours, cell supernatants of all the wells are discarded, and the cells are replaced by a PRIM-1640 serum-free culture medium, wherein each well is 0.5 mL.
2.4 detection of lentivirus infection efficiency
Starting 36h after inoculation, the fluorescence change of the cells in each well is observed under a fluorescence inverted microscope every 12h, and images are retained.
Collecting cell precipitates of each well 108h after inoculation, resuspending the cell precipitates by PBS, centrifuging the cell precipitates to remove supernatant, repeating the steps for 3 times, then resuspending the cells of each well by using 4 percent paraformaldehyde with the volume of 300 mu L respectively, collecting the cell precipitates in a flow cytometry detection tube, placing the cell precipitates on ice in a dark place, and detecting FITC channel fluorescent signals by using a flow cytometer.
Experimental quantification data were analyzed and imaged by GraphPad Prism 6 statistical analysis software,
2.5 results and analysis
The results of microscopic imaging of IPAM cells at the 36hpi, 48hpi, 60hpi, 72hpi, 84hpi, 96hpi, and 108hpi time points for each experimental group are shown in FIGS. 8-14.
The flow cytometric grouping results of the individual well IPAM cells detoxified at Lentivirus-gfp at MOI of 100 are shown in FIG. 15. According to statistical analysis, the infection efficiency of IPAM cells reaches 40% at the MOI of 100 infection level, and the difference is significant compared with the control.
Example triple lentivirus infection of BMDM cells
Experimental procedures BMDM cells were infected according to example two. The results of flow cytometry cell clustering of BMDM cells in each well, which were inoculated at an MOI of 1000 with Lentivirus-gfp, are shown in FIG. 16. Statistical analysis showed that at MOI 100 infection level, the infection efficiency of BMDM cells also reached 25%, with a significant difference compared to the control.
The above-mentioned embodiments are merely preferred embodiments of the present invention, which are merely illustrative and not restrictive, and it should be understood that other embodiments may be easily made by those skilled in the art by replacing or changing the technical contents disclosed in the specification, and therefore, all changes and modifications that are made on the principle of the present invention should be included in the scope of the claims of the present invention.
SEQUENCE LISTING
<110> Lanzhou veterinary research institute of Chinese academy of agricultural sciences City agricultural research institute of China academy of agricultural sciences
<120> siRNA and kit for knocking down pig SAMHD1 gene expression and application thereof
<130> 2021
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 21
<212> DNA
<213> siRNA sense strand
<400> 1
gcaccugguu aauucuaaut t 21
<210> 2
<211> 21
<212> DNA
<213> siRNA antisense strand
<400> 2
auuagaauua accaggugct t 21
Claims (5)
1. The application of the kit containing the siRNA for knocking down pig SAMHD1 gene expression in improving the efficiency of infecting pig cells with lentiviruses is characterized in that a sense strand of the siRNA is a base sequence shown in SEQ ID NO.1, and an antisense strand of the siRNA is a base sequence shown in SEQ ID NO. 2.
2. The use of claim 1, wherein the kit further comprises a lentiviral packaging plasmid; the lentivirus packaging plasmid comprises three circular plasmids of pLenti-gfp, pMD2G and pSPAX 2.
3. The use according to claim 1, wherein the lentivirus is packaged using co-transfection with three circular plasmids in a molar ratio of 1:1:1, pLenti-gfp, pMD2G and pSPAX 2.
4. The use of claim 1, wherein the siRNA is transfected into a cell at a final concentration of 150nM/μ L.
5. The use of claim 1, wherein the siRNA is transfected into the cell at a time prior to 12 hours prior to infection of the cell by the lentivirus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111117202.0A CN113846099B (en) | 2021-09-23 | 2021-09-23 | siRNA for knocking down pig SAMHD1 gene expression, kit and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111117202.0A CN113846099B (en) | 2021-09-23 | 2021-09-23 | siRNA for knocking down pig SAMHD1 gene expression, kit and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113846099A CN113846099A (en) | 2021-12-28 |
CN113846099B true CN113846099B (en) | 2022-04-22 |
Family
ID=78979383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111117202.0A Active CN113846099B (en) | 2021-09-23 | 2021-09-23 | siRNA for knocking down pig SAMHD1 gene expression, kit and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113846099B (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2831095T3 (en) * | 2012-03-30 | 2019-02-18 | Immune Design Corp | LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN |
CN104164442B (en) * | 2014-01-22 | 2018-05-18 | 中国农业科学院上海兽医研究所 | Pig SAMHD1 genes, albumen, monoclonal antibody and its application |
CN104450784B (en) * | 2014-11-18 | 2017-03-22 | 浙江大学 | Method for establishing SAMHD1 gene knockout cell line |
CN110249046A (en) * | 2016-12-05 | 2019-09-17 | 朱诺治疗学股份有限公司 | The generation of engineering cell for adoptive cellular therapy |
-
2021
- 2021-09-23 CN CN202111117202.0A patent/CN113846099B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113846099A (en) | 2021-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2077326A1 (en) | Novel nucleic acid | |
CN110066852B (en) | Method and system for detecting CRISPR/Cas PAM sequence in mammalian cell | |
CN109182562B (en) | miRNA apla-mir-25-42 related to follicular development of laying ducks as well as detection primer, inhibitor and application thereof | |
CN113881707B (en) | Product, method and application for regulating and controlling immune suppression effect of umbilical cord mesenchymal stem cells | |
CN109402118B (en) | miRNA apla-mir-145-4 related to follicular development of laying ducks as well as detection primer, inhibitor and application thereof | |
CN113846099B (en) | siRNA for knocking down pig SAMHD1 gene expression, kit and application thereof | |
CN113925863B (en) | Application of Ivacaftor in preparation of medicine for inhibiting novel coronavirus SARS-CoV2 | |
CN109652529B (en) | Osteoporosis specific miRNA, composition and diagnosis and treatment application thereof | |
CN114790463B (en) | Construction method and application of monoclonal cell strain for stably transfecting CRISPR/dCAS9 system | |
CN106244593A (en) | A kind of microRNA regulating Cornu Cervi Pantotrichum young pilose antler skin fast-growth and application thereof | |
CN105200059A (en) | SiRNA for targeted inhibition of mouse UCP2 gene expression and construction of expression vector thereof | |
CN112779324B (en) | Method for single cell detection and analysis and uses thereof | |
WO2014198833A1 (en) | Ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention | |
CN109266684B (en) | Method for constructing animal model with pathogen infection sensitivity | |
CN108441496B (en) | shRNA sequence for inhibiting chicken SOX5 gene expression and application thereof | |
CN103173446A (en) | Construction method of recombinant adeno-associated virus vector of targeting interference SOCS1 gene and application of construction method | |
CN111926018A (en) | Application of substance for reducing USP1 expression in preparation of medicine for treating children T-line acute lymphoblastic leukemia | |
CN109055429B (en) | Mouse osteogenic-like cell lentiviral vector targeting RunX2 gene and construction method thereof | |
CN113122578A (en) | Electric shock transformation method for efficiently constructing cell library | |
CN113151358B (en) | Construction method and application of ZNF382 stably transfected diffuse large B cell lymphoma cell strain | |
Manicone et al. | Expression of HTLV-1 Genes in T-Cells Using RNA Electroporation | |
CN116726180B (en) | Application of NAT10 inhibitor in polycythemia vera | |
CN110652522B (en) | Application of miR-2052in preparation of anti-liver cancer drugs | |
CN114032238B (en) | Application of gga-miR-146a-5p inhibitor in preparation of anti-J subgroup avian leukosis virus infection medicines | |
CN101463351A (en) | External leader sequence for guiding RNase P ribozyme and use thereof in anti-HCMV medicament preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |